What was known before:
Anti-VEGF agents are in widespread use as adjuncts to vitreoretinal surgery for advanced proliferative retinopathy. Detailed data on surgical outcomes is limited to small uncontrolled studies, although there is now good quality evidence that prior injection of bevacizumab reduces post-operative vitreous cavity haemorrhage. Ranibizumab has been reported to reduce intra-operative haemorrhage.

What this study adds:
This pilot randomised clinical trial investigated ranibizumab pre-treatment before diabetic vitrectomy-delamination surgery. The study shows that the likely effect size of ranibizumab on final visual acuity is likely to be small, and with the heterogeneity of outcomes in this condition, a further definite study powered to detect a significant difference is unlikely to be feasible given the subject numbers required. Clinicians will likely therefore continue to use anti-VEGF agents in this condition based on individual experience and preference.
Ranibizumab pre-treatment in Diabetic Vitrectomy - a pilot randomised controlled trial (the RaDiVit study)

Ranibizumab in diabetic vitrectomy (RaDiVit)

Professor James W Bainbridge
Institute of Ophthalmology
11-43 Bath Street
London EC1V 9EL
United Kingdom
Phone: +44 (0) 207 608 4023
Fax: +44 (0) 207 608 6991
j.bainbridge@ucl.ac.uk

Oliver Comyn1A, Louisa Wickham1A, David G Charteris1A, Paul M Sullivan1A, Eric Ezra1A, Zdenek Gregor1A, G William Aylward1A, Lyndon da Cruz1A, David Fabinyi1A, Tunde Peto1A,B, Marie Restori1A,C, Wen Xing1A, Catey Bunce1A, Philip G Hykin1A, and James W Bainbridge1A.

A National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital and University College London (UCL) Institute of Ophthalmology
B Reading Centre, Moorfields Eye Hospital
C Department of Ultrasound, Moorfields Eye Hospital

1 162 City Road
London, EC1V 2PD
United Kingdom

Supported by an unrestricted research grant from Novartis Pharmaceuticals UK Ltd., Frimley, United Kingdom; the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital National Health Service Foundation Trust and University College London Institute of Ophthalmology; and a multi-user equipment grant from The Wellcome Trust [099173/Z/12/Z].
ABSTRACT

Purpose
Our aim was to evaluate the impact of intravitreal ranibizumab pre-treatment on the outcome of vitrectomy surgery for advanced proliferative diabetic retinopathy. The objective was to determine the feasibility of a subsequent definitive trial and estimate the effect size and variability of the outcome measure.

Methods
We performed a pilot randomised double-masked single-centre clinical trial in 30 participants with tractional retinal detachment associated with proliferative diabetic retinopathy. Seven days prior to vitrectomy surgery, participants were randomly allocated to receive either intravitreal ranibizumab (Lucentis®, Novartis Pharmaceuticals UK Ltd.) or subconjunctival saline (control). The primary outcome was best-corrected visual acuity 12 weeks following surgery.

Results
At 12 weeks the mean (SD) visual acuity was 46.7 (25) ETDRS letters in the control group and 52.6 (21) letters in the ranibizumab group. Mean visual acuity improved by 14 (31) letters in the control group and by 24 (27) letters in the ranibizumab group. We found no difference in the progression of tractional retinal detachment prior to surgery, the duration of surgery or its technical difficulty. Vitreous cavity haemorrhage persisted at 12 weeks in 2 of the control group but none of the ranibizumab group.

Conclusions
Ranibizumab pre-treatment may improve the outcome of vitrectomy surgery for advanced proliferative diabetic retinopathy by reducing the extent of postoperative vitreous cavity haemorrhage. However, the effect size appears to be modest; we calculate that a definitive study to establish a minimally important difference of 5.9 letters at a significance level of P<0.05 would require 348 subjects in each arm.
INTRODUCTION

Advanced proliferative retinopathy is characterized by fibrovascular proliferation, vitreous haemorrhage and tractional retinal detachment (Figure 1A and B). This condition is conventionally managed by vitreoretinal surgery, the outcome of which can be limited by recurrent postoperative vitreous cavity haemorrhage. The intraocular administration of therapeutic anti-vascular endothelial growth factor (VEGF) antibodies is variably used as an adjunct to vitrectomy with the aim of improving the outcome by facilitating safe delamination of fibrovascular membranes and reducing the incidence of post-operative vitreous cavity haemorrhage. However the value of adjunctive administration of antiVEGF antibodies has yet to be established with confidence.

Intravitreal ranibizumab pre-treatment, 7 days prior to vitrectomy surgery for diabetic tractional retinal detachment, can reduce intraoperative haemorrhage. The aim of the present study was to evaluate its impact on postoperative outcomes. The objective was to measure the effect on visual acuity and ascertain the number of participants that would be needed to determine such an effect with confidence.

MATERIALS AND METHODS

We performed a randomised double-masked parallel group pilot study at Moorfields Eye Hospital (NCT01306981). The study conformed to the Declaration of Helsinki and was approved prospectively by the Central London Research Ethics Committee 1 of the UK National Research Ethics Service. All participants gave their informed consent to participate in the research prior to enrolment.

We included 30 eyes of 30 adult participants having vitrectomy and delamination surgery for advanced proliferative diabetic retinopathy with fibrovascular complexes and/or tractional retinal detachment. Eyes with persistent vitreous haemorrhage could be included because of the use of ultrasonography to evaluate attachment of the retina. We excluded eyes having
planned combined cataract and vitrectomy, those with only a single focal point of
vitreoretinal attachment apparent on clinical examination or ultrasonography, and those with
cataract or uncontrolled glaucoma. We excluded individuals with visual acuity in the
central eye of 3/60 or poorer, hypersensitivity to the active substance or excipients,
and cerebrovascular, cardiovascular or peripheral vascular disease.

Seven days (±1 day) prior to vitrectomy surgery, participants were randomly allocated 1:1 to
receive either intravitreal ranibizumab (Lucentis®, 0.5 mg in 0.05 ml solution for injection,
Novartis Pharmaceuticals UK Ltd., Frimley, United Kingdom), or subconjunctival saline
control (sodium chloride, 0.05ml of 0.9% solution for injection) using a 1ml syringe and 30-
gauge needle. Randomisation was performed using random permuted blocks of varying
sizes. The allocation sequence was held by the trial statistician and concealed from the
investigator enrolling and assessing participants. An unmasked investigator administered the
study agents. Participants in both groups were prepared identically using topical anaesthetic
and povidone iodine; topical levofloxacin was administered immediately prior to the injection
and 4 times daily for 4 days. The participants, operating surgeons and assessing
investigators were masked to treatment allocation. Participants were assessed at baseline,
immediately prior to surgery, and at 6 weeks and 12 weeks following surgery.

Experienced vitreoretinal surgeons performed 20-gauge pars plana vitrectomy and en-bloc
delamination of fibrovascular membranes, panretinal endo-photocoagulation, with retinopexy
and endotamponnade if indicated. We recorded the duration of surgery, the number of back-
flush cannula and endodiathermy applications required to control haemorrhage, retinal
breaks, intraoperative bleeding score (0-none; 1-mild, stopped by bottle elevation; 2-
moderate, forming clots or persistent; 3-severe, covering half of posterior pole) and the
anticipated surgical complexity score (Castellarin et al.).

To investigate the impact of ranibizumab on the extent of tractional retinal detachment prior
to surgery we examined the study eye prior to administration of the study agent and one
week later on the day of surgery by slit-lamp biomicroscopy and ultrasonography (Acuson
Sequoia 512 scanner, 14 MHz linear probe; Siemens Medical Solutions USA; Mountain
View, CA, USA). To investigate the impact on retinal neovascularisation and ischaemia we
performed fluorescein angiography (unless precluded by vitreous haemorrhage); masked
assessors at Moorfields Reading Centre measured the greatest linear dimension and area of
the foveal avascular zone, and the grade of perifoveal capillary non-perfusion.

The primary outcome measure was Early Treatment Diabetic Retinopathy Study (ETDRS)
best-corrected visual acuity 12 weeks following surgery. Secondary outcome measures
included the extent of fractional retinal detachment and macular perfusion at the time of
surgery; the technical ease of vitrectomy surgery including duration, instrument usage and
intra-operative haemorrhage; and the presence of post-operative vitreous cavity
haemorrhage. This was graded using a previously described scale from 0 – 3 (0 – no
haemorrhage, clear view; 1 – minor haemorrhage with fundus details visible; 2 – moderate
haemorrhage with only disc and major vessels visible; 3 – severe haemorrhage with fundus
details not visible). 11

For this pilot trial we performed no formal sample size calculation but estimated that 30
subjects would be sufficient to explore the feasibility of a subsequent definitive trial and to
enable calculation of its sample size. The Trial Steering Group approved a statistical
analysis plan prior to analysis of data. We compared baseline characteristics of the
participants allocated to the 2 treatment arms. Normality was assessed by inspection of
histograms. We calculated summary statistics using STATA statistical software (version 12,
StataCorp LP, College Station, TX, USA).
RESULTS

We included 30 eyes of 30 participants and randomly allocated 15 eyes to each arm of the study, and none were lost to follow-up. All eyes had been managed for proliferative retinopathy by panretinal photocoagulation prior to enrolment. The participants in the 2 arms were similar (Table 1) though the overall complexity score derived from ultrasound assessment of tractional detachment was slightly higher in the ranibizumab group (Table 2).

At 12 weeks following surgery the mean (standard deviation) visual acuity was 46.7 (25) ETDRS letters in the control group and 52.6 (21) letters in the ranibizumab group (Figure 2). The mean visual acuity improved by 14 (31) letters in the control group and by 24 (27) letters in the ranibizumab group.

One participant in each group developed new tractional retinal detachment following the study injection; in neither instance did this involve the macula (Table 2). The mean height of TRD increased slightly in control eyes following the study injection. No other change in TRD dimension exceeded the limit of resolution (±1.6 mm) and the overall ultrasound-derived complexity score was unchanged in both groups.

The median duration of surgery was greater in the ranibizumab group (63 minutes) than the control group (51 minutes) (Table 3; P=0.53); intraoperative haemorrhage scores were similar as were the number of endodiathermy and back-flush cannula applications. The median surgeon-defined complexity score based on retinal features present at the start of surgery was slightly higher for the ranibizumab group but the median overall subjective surgical difficulty score was lower and there were fewer iatrogenic retinal breaks.
Any residual vitreous cavity haemorrhage following vitrectomy surgery resolved progressively in both groups. At six weeks after surgery two of fifteen subjects in the control group, and one of thirteen subjects in the ranibizumab group who had not received silicone oil had visible vitreous cavity haemorrhage. While this was moderate in the ranibizumab group, in the control group both had a severe grade of haemorrhage. Moderate or severe residual haemorrhage persisted in 2 eyes of the control group at 12 weeks following surgery, but had fully resolved in the subject in the ranibizumab group.

At baseline, fluorescein angiograms were gradable in only a minority of participants (3 of the control group and 5 of the ranibizumab group) owing to media opacity and/or distortion of foveal anatomy in the majority. All gradable angiograms demonstrated moderate to severe perifoveal capillary non-perfusion. At 12 weeks, the mean (SD) foveal avascular zone greatest linear dimension was 637 (236) µm in the control group (n=9) and 765 (576) µm in the ranibizumab group (n=10); the foveal avascular zone area was 0.315 (0.147) mm² in the control group and 0.403 (0.562) mm² in the ranibizumab group. The median total score for perifoveal capillary non-perfusion was 14 in both groups, indicating scores of 3-4 (moderate to severe) in each of the four quadrants.

Ocular and non-ocular adverse events were in keeping with previously published trials of anti-VEGF agents. The most common adverse event was upper respiratory tract infection which occurred more commonly in the control group. There were no arterial thrombo-embolic events or cases of endophthalmitis. There was one serious adverse event in each group. One participant in the control group was admitted to hospital for management of hypoglycaemia 10 weeks after surgery, and one participant in the ranibizumab group was admitted for management of raised intraocular pressure following vitrectomy surgery, an event judged unlikely to be related to study drug administration. Vitreous cavity haemorrhage was more frequent in the control group than in the ranibizumab group.
The results of this trial confirm significant improvement in mean visual acuity 12 weeks following vitreoretinal surgery for advanced proliferative retinopathy, with or without ranibizumab pre-treatment, consistent with previous reports. Our findings also suggest a modest additional benefit of intravitreal injection of ranibizumab one week prior to surgery, with higher mean visual acuity and greater mean improvement in visual acuity at 12 weeks. The difference in acuity in this pilot study is not statistically significant. On the basis of these data, we calculate that 348 subjects in each group (696 in total) would be required to determine a clinically relevant treatment difference of 5.9 letters with 90% power and 5% significance, allowing for 5% loss to follow-up.

Our findings of reduced postoperative vitreous cavity haemorrhage associated with ranibizumab pre-treatment in vitrectomy surgery are consistent with a previous report that this also reduces intraoperative haemorrhage during surgery. Earlier studies have shown conflicting results regarding the utility of bevacizumab in preventing recurrent haemorrhage, for example Romano et al. found that although pre-operative injection could reduce the number of recurrent haemorrhages, giving the drug as an intra-operative adjunct did not prevent post-operative vitreous cavity haemorrhage. Data from the 2015 update to the Cochrane review of bevacizumab for the prevention of post-operative vitreous cavity haemorrhage suggest that treatment results in 130 fewer people per 1000 experiencing early post-operative haemorrhage, although there is considerable heterogeneity of methodology in the trials included in this systematic review.

We found that ranibizumab pre-treatment was associated with a lower intraoperative bleeding score, greater reduction in retinal neovascularisation and lower prevalence of persistent vitreous cavity haemorrhage. However, in contrast to previous studies and a meta-analysis of these studies that have reported shorter surgical duration or fewer instrument exchanges following anti-VEGF prior to surgery for proliferative diabetic
retinopathy,\textsuperscript{4,7} we found that the median surgical complexity score was no lower, the mean
duration of vitrectomy was no shorter, and the use of the backflush cannula and
endodiathermy were similar.

Previous studies have highlighted concerns about the development or progression of
tractional retinal detachment associated with progressive fibrosis following intravitreal
administration of anti-VEGF agents, especially in the absence of prior panretinal
photocoagulation.\textsuperscript{13,14} Despite the presence of dense media opacity in many, we were able
to determine the impact of ranibizumab pre-treatment on the extent of tractional retinal
detachment prior to surgery in all participants by the use of ultrasonography. In our study, in
which all subjects had been managed previously by panretinal photocoagulation, we
identified no effect of ranibizumab injection on extension of retinal detachment after 7 days.
We chose this interval between injection and surgery to maximise the possibility of benefit
while minimising the risk of harm, and this finding from ultrasound evaluation suggests that
administering ranibizumab in the setting of previously treated proliferative retinopathy may
be safe in this regard.

We identified significant macular ischemia in the participants in both groups but found no
evidence of an impact of intervention in either. Although we conclude that its safety profile
appears to be favourable, the number of subjects in whom angiography was feasible is
insufficient to draw firm conclusions about the impact of ranibizumab injection on the extent
of macular ischemia in this context.

The strengths of our study are that it was randomised and double-masked with a sham
control arm. Since the study included multiple surgeons, all of whom were experienced in
vitrectomy surgery for advanced diabetic retinopathy, the findings are broadly generalisable.
The ability to draw firm conclusions is limited by the small number of subjects included and
the inherent heterogeneity of the condition, in particular the variability of management of
proliferative retinopathy prior to enrolment in the study and difficulty in controlling for variable
amounts of prior panretinal photocoagulation. However, the results provide a valuable
indication of the substantial size of the trial that would be needed to confirm with confidence
the impact of ranibizumab pre-treatment in vitrectomy surgery for advanced diabetic
retinopathy.

ACKNOWLEDGEMENTS

We are grateful to David Yorston and Edward Hughes for constructive advice on design of
the trial.

CONFLICT OF INTEREST

The study was part funded by an unrestricted research grant from Novartis Pharmaceuticals,
UK, Ltd.

Dr Comyn has received travel support from Novartis.

REFERENCES

1. Yorston D, Wickham L, Benson S, et al. Predictive clinical features and outcomes of
3. Chen E, Park C. Use of intravitreal bevacizumab as a preoperative adjunct for
tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina
(Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe
42.


FIGURE LEGENDS

Figure 1A and B – Colour fundus photograph (A) and ultrasound image (B) to show advanced proliferative diabetic retinopathy. The fundus image shows evidence of fibrovascular proliferation, pre-retinal haemorrhage and tractional retinal detachment involving the macula, while the ultrasound shows partial posterior vitreous detachment with vitreous attachment to tractional retinal detachment. Calliper placement shows measurement of height and longitudinal base dimension of tractional detachment.

Figure 2 – Box plots to show visual acuity (VA) by treatment group, shown as mean ± standard deviation Early Treatment Diabetic Retinopathy Study letter score.
Table 1. Participants in a pilot randomised study of ranibizumab pre-treatment in diabetic vitrectomy

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Ranibizumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of participants</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>Female gender (number of participants)</td>
<td>9 (60%)</td>
<td>3 (20%)</td>
</tr>
<tr>
<td>Age (years); mean (SD)</td>
<td>48.7 (18)</td>
<td>57.1 (14)</td>
</tr>
<tr>
<td>Ethnicity: (number of participants)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White or white British</td>
<td>8 (53%)</td>
<td>8 (53%)</td>
</tr>
<tr>
<td>Black or black British</td>
<td>2 (13%)</td>
<td>2 (13%)</td>
</tr>
<tr>
<td>Asian or Asian British</td>
<td>2 (13%)</td>
<td>3 (20%)</td>
</tr>
<tr>
<td>Other</td>
<td>3 (20%)</td>
<td>1 (7%)</td>
</tr>
<tr>
<td>Not recorded</td>
<td>0</td>
<td>1 (7%)</td>
</tr>
<tr>
<td>Type of diabetes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type 1 (number of participants)</td>
<td>6 (40%)</td>
<td>4 (27%)</td>
</tr>
<tr>
<td>Type 2 (number of participants)</td>
<td>9 (60%)</td>
<td>11 (73%)</td>
</tr>
<tr>
<td>Duration of diabetes (years); median (IQR)</td>
<td>21 (15, 28)</td>
<td>19 (10, 23)</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>132 (22)</td>
<td>128 (22)</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>75 (9)</td>
<td>78 (11)</td>
</tr>
<tr>
<td>HbA1c (glycosylated haemoglobin, %)</td>
<td>9.3 (1.8) (n=13)</td>
<td>8.2 (1.1) (n=14)</td>
</tr>
</tbody>
</table>

**Ocular characteristics**

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Ranibizumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETDRS letter score</td>
<td>32.3 (19)</td>
<td>28.5 (27)</td>
</tr>
<tr>
<td>RAPD present (number)</td>
<td>3 (20%)</td>
<td>4 (27%)</td>
</tr>
<tr>
<td>Rubeosis present (number)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Anterior chamber inflammation grade (0-4)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Intraocular pressure (mmHg)</td>
<td>16.5 (4)</td>
<td>16.8 (3)</td>
</tr>
<tr>
<td>Lens status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pseudophakic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cataract grade 0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>3 (20.0%)</td>
<td>5 (33.3%)</td>
</tr>
<tr>
<td>2</td>
<td>4 (26.7%)</td>
<td>4 (26.7%)</td>
</tr>
<tr>
<td>3</td>
<td>6 (40.0%)</td>
<td>5 (33.3%)</td>
</tr>
<tr>
<td>4</td>
<td>1 (6.7%)</td>
<td>1 (6.7%)</td>
</tr>
<tr>
<td>0</td>
<td>1 (6.7%)</td>
<td>0</td>
</tr>
<tr>
<td>Vitreous haemorrhage score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 (no haemorrhage)</td>
<td>3 (20.0%)</td>
<td>6 (40.0%)</td>
</tr>
<tr>
<td>1 (minor haemorrhage)</td>
<td>8 (53.3%)</td>
<td>5 (33.3%)</td>
</tr>
<tr>
<td>2 (moderate haemorrhage - disc and large vessels visible)</td>
<td>2 (13.3%)</td>
<td>1 (6.7%)</td>
</tr>
<tr>
<td>3 (severe haemorrhage - no fundus view)</td>
<td>2 (13.3%)</td>
<td>3 (20.0%)</td>
</tr>
</tbody>
</table>
Data shown as mean (SD) for normally distributed variables. ETDRS - Early Treatment Diabetic Retinopathy Study; RAPD - relative afferent pupillary defect.
Table 2. Tractional retinal detachment characteristics following study injection in a randomised trial of ranibizumab prior to diabetic vitrectomy.

<table>
<thead>
<tr>
<th>Time-point</th>
<th>Control</th>
<th>Ranibizumab</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>1 week</td>
</tr>
<tr>
<td><strong>TRD characteristics from ultrasound</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of eyes with TRD</td>
<td>6 (40%)</td>
<td>7 (47%)</td>
</tr>
<tr>
<td>Number of eyes with macula TRD involving</td>
<td>5 (83%)</td>
<td>5 (71%)</td>
</tr>
<tr>
<td>Dimensions of TRD (mean (SD))</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height (mm)</td>
<td>2.2(0.5)</td>
<td>2.5(0.6)</td>
</tr>
<tr>
<td>Base (mm)</td>
<td>11.9(5.0) x 12.6(5.3) x 11.9(4.7) x 12.1(5.0)</td>
<td>13.2(4.6) x 13.5(4.4) x 11.5(5.3) x 12.5(6.2)</td>
</tr>
<tr>
<td>Ultrasound-derived complexity score (0-8; median)</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td><strong>TRD characteristics from colour imaging (baseline only)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number with gradable images</td>
<td>9</td>
<td>-</td>
</tr>
<tr>
<td>Absent</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Hammock</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Diffuse Central</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Tabletop</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

TRD - tractional retinal detachment; RRD - rhegmatogenous retinal detachment.
Table 3. Intraoperative parameters in a trial of ranibizumab in diabetic vitrectomy

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control</th>
<th>Ranibizumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgeon-determined complexity score 0 (simple) - 8 (highly complex)</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Duration of vitrectomy (mins) median (interquartile range)</td>
<td>51 (38-82)</td>
<td>63 (42-87)</td>
</tr>
<tr>
<td>Intraoperative bleeding score (median score) 0 (none) - 3 (severe)</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Endodiathermy applications (mean)</td>
<td>1.5</td>
<td>1.1</td>
</tr>
<tr>
<td>Backflush cannula applications (mean)</td>
<td>2.8</td>
<td>2.5</td>
</tr>
<tr>
<td>Number of iatrogenic retinal breaks (total)</td>
<td>15</td>
<td>12</td>
</tr>
<tr>
<td>Tamponnade agent (number of participants)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>3 (20%)</td>
<td>3 (20%)</td>
</tr>
<tr>
<td>Sulphur hexafluoride</td>
<td>11 (73%)</td>
<td>9 (60%)</td>
</tr>
<tr>
<td>Perfluoropropane</td>
<td>1 (7%)</td>
<td>1 (7%)</td>
</tr>
<tr>
<td>Silicone oil</td>
<td>0 (0%)</td>
<td>2 (13%)</td>
</tr>
<tr>
<td>Overall surgical difficulty score (median score) Scale 0 (simple) - 4 (very difficult)</td>
<td>3</td>
<td>2</td>
</tr>
</tbody>
</table>